The third session of the inquiry into cancer
services will examine NHS cancer treatments,
including Action Radiotherapy’s finding that 50% of
radiotherapy centres have out of date machines,
and claims that it would cost an extra £87 million a year to
replace them on a rolling basis. The Committee is also
expected to consider to what extent workforce shortages
and burnout are affecting cancer care.
MPs will hear from academics, clinicians, and organization
leaders to understand why the UK lags behind comparable
countries on cancer treatment
outcomes. The Committee is also expected
to focus on why novel cancer treatments are less
common in the UK than in comparable countries, and
how changes to funding and the NICE approval process
might remedy this.
Witnesses at 09:30:
· Dr Philippa
Hetherington, cancer patient
From 09:40 approx:
· Professor David
Cunningham, Chair at Association of Cancer
Physicians
· Professor Mike
Griffin, President at Royal College of Surgeons of
Edinburgh
· Professor Pat
Price, Consultant Clinical Oncologist and Chair at Action
Radiotherapy
From 10:40 approx:
· Professor Nick
James, Prostate and Bladder Cancer Team Leader at Institute of
Cancer Research
·
Baroness Delyth Morgan, Chief Executive Officer
at Breast Cancer Now
· David Watson,
Executive Director of Economic, Health and Commercial Policy at
The Association of the British Pharmaceutical Industry
(ABPI)
Further information:
The inquiry into cancer services was launched in July. It
aims to investigate why the UK continues to lag behind comparable
countries in cancer outcomes. The disruption to cancer
services from COVID-19 and actions to mitigate it will also
be considered. The second session examined
why the UK falls behind on early cancer diagnosis.
